Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

checksurshorts 121 posts  |  Last Activity: May 22, 2015 3:04 PM Member since: Dec 1, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    New job opening

    by checksurshorts May 22, 2015 3:01 PM
    checksurshorts checksurshorts May 22, 2015 3:04 PM Flag

    SUMMARY:

    Reporting to the Global Head of Program Management, this position will be accountable for all necessary project planning, scheduling, tracking, managing and project direction required for the successful and timely completion of projects within Technical Operations including:

    • Technology Transfer

    • New Product Launches

    • Assay Transfer

    • Packaging/labeling

    • Process Scale-up

    • Process Improvements

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts May 22, 2015 3:01 PM Flag

    Project Manager - Technical Operations

    Sentiment: Strong Buy

  • Vertex in Talks With Other Cystic Fibrosis Drugmakers on Combos
    2015-05-19 15:59:21.268 GMT

    By Catherine Larkin
    (Bloomberg) -- Vertex in talks with “most if not all”
    smaller cos. that are also developing drugs to treat cystic fibrosis about potential combination therapies, CEO Jeff Leiden says at UBS health conf. in New York.

    * VRTX has become “partner of choice” for many small cos.

    with only one drug, pretty clear that one component alone
    isn’t going to be enough

    * Pleased with how these talks are progressing, says may be
    more news on this later this yr

    * NOTE: Other cos. developing cystic fibrosis drugs include
    Corbus Pharmaceuticals, Galapagos, Insmed, Protalix, PTC
    Therapeutics

    Sentiment: Strong Buy

  • Reply to

    How sweet it is!!!

    by jsblvbjb May 20, 2015 4:10 PM
    checksurshorts checksurshorts May 20, 2015 8:56 PM Flag

    No wonder WL was "excited" to present these posters. Thanks!!!

    Sentiment: Strong Buy

  • checksurshorts checksurshorts May 20, 2015 1:06 PM Flag

    I personally think insmed will get to file early with FDA when early good data comes out. This trial is recruiting only those that are most responsive to the treatment and conversion happened fairly quickly. Duplicating the results of the previous trial under the "proper" endpoint would allow the FDA to remain within process. Remember, insmed was approached by the gov to do NTM. Just my opinion.

    Sentiment: Strong Buy

  • Reply to

    Frankfort Germany

    by justarook04 Apr 9, 2015 7:22 AM
    checksurshorts checksurshorts May 19, 2015 12:56 PM Flag

    Yes, all good.

    He just mentioned the Tobi for CF at 15-20 EU per 6 months and Arykace would match. He then said for NTM would be 30-40 EU per year but I don't think he meant Tobi was used for NTM just that there would be a similar price point.

    Good luck.

    Sentiment: Strong Buy

  • Reply to

    Frankfort Germany

    by justarook04 Apr 9, 2015 7:22 AM
    checksurshorts checksurshorts May 19, 2015 12:12 PM Flag

    Will had said $50-$100K in US and he believes there is very good support at the upper end of the range. They would push value for the money but didn't want to hurt uptake by pricing too high.

    In Europe he said they would match other treatments such as Tobi which is 15-20 EU per 6 months and NTM would be 30-40 EU per year.

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts May 18, 2015 9:53 PM Flag

    Interesting reference to the 8.3B InterMune buyout at about 17 minutes in.

    US pricing: $50-$100k

    Excited to release some previously embargoed NTM data on Wed. at American Thoracic Society meeting along with the INS1009 posters.

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts May 18, 2015 11:20 AM Flag

    Tried to post before.

    Sentiment: Strong Buy

  • Made me think of ALS and iPLEX which I believe can already cross BBB. Could this help make it more effective though?

    From UK Independent:

    "Doctors can now inject drugs straight into people’s brains, after making a major discovery in breaking through the barrier that keeps the nervous and circulatory systems apart.

    The blood-brain barrier (BBB) keeps us safe by ensuring that chemicals and microbes can't get through to our clean brain and cause it problems. But it filters out good and intentional molecules too, and has proven a stumbling block for doctors’ aim to get drugs straight to where they are needed.

    But new research claims to have found a way through the lock, developing special molecules that can trick the BBB into think that they should be let through by exploiting the mechanism that let nutrients into the brain. A team from the Canadian National Research Council has made carrier molecules that help disease-fighting ones break through, where they can then release the therapeutics they need, straight into the nervous system."

    Sentiment: Strong Buy

  • Reply to

    Form 4 Vice President Quality, Mark Quigley

    by ries123 May 13, 2015 4:57 PM
    checksurshorts checksurshorts May 13, 2015 6:27 PM Flag

    While I can fully understand 1-3, I'm hoping for #4:)

    Sentiment: Strong Buy

  • Reply to

    Form 4 Vice President Quality, Mark Quigley

    by ries123 May 13, 2015 4:57 PM
    checksurshorts checksurshorts May 13, 2015 5:29 PM Flag

    Look for something shiny on the road:)

    Sentiment: Strong Buy

  • Reply to

    Oh,,I didn't think about that!!

    by zake1 May 12, 2015 3:36 PM
    checksurshorts checksurshorts May 13, 2015 11:29 AM Flag

    Great point bohemian. Also, what could the technology do to prevent resistance for new antibiotics such as Teixobactin since the whole body doesn't need to be exposed? Resistance is something the FDA is very interested in.

    Sentiment: Strong Buy

  • Reply to

    On thing to add to Zake's points

    by fasano98 May 13, 2015 9:31 AM
    checksurshorts checksurshorts May 13, 2015 11:16 AM Flag

    No prob. I believe Abscessus is the more difficult bug to eradicate.

    From previous trial: "History of chronic infection with either Mycobacterium avium complex or Mycobacterium abscessus or mixed infection with both species (defined as at least 2 documented positive cultures in the prior 2 years, of which at least one was obtained in the 6 months prior to screening)."

    From new study: "A Randomized, Open-label, Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients With Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC) Who Are Refractory to Treatment"

    Sentiment: Strong Buy

  • Reply to

    On thing to add to Zake's points

    by fasano98 May 13, 2015 9:31 AM
    checksurshorts checksurshorts May 13, 2015 10:58 AM Flag

    I have that individual on ignore so I won't get to see it when he posts that the difference between the two studies is not only the primary endpoint but that they are only recruiting NTM patients with the strain of bacteria that was most receptive (culture conversion) to Arykace.

    Sentiment: Strong Buy

  • Reply to

    ARDM and NTM

    by checksurshorts May 12, 2015 3:45 PM
    checksurshorts checksurshorts May 12, 2015 3:52 PM Flag

    Probably right. So, with a current market cap of about $100M would it be better to buy them or just do our own formulation? They do have something in P-3 for different indication.

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts May 12, 2015 3:45 PM Flag

    Only mouse

    "Scientists from the Oregon State University, Corvallis (OSU) and Aradigm Corporation (ARDM) (the “Company”) demonstrated that Aradigm’s investigational drugs Lipoquin® and Pulmaquin® significantly reduced the growth of the pulmonary non-tuberculous mycobacteria infection (PNTM) after 3 weeks of once daily respiratory tract dosing in mice. The number of colony forming units of Mycobacterium Avium Subsp Hominissuis was reduced by 79% and 77% by Lipoquin and Pulmaquin, respectively (p

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts May 7, 2015 5:24 PM Flag

    Someone posted on Twitter that they reiterated market outperform rating and $25 PT based on 1Q 15 financials. Do not have a link at this time so haven't verified.

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts May 7, 2015 3:03 PM Flag

    Insmed looking for a full time recruiter and for two more interns.

    Sentiment: Strong Buy

  • "The Associate Director of Enterprise Systems provides expertise, and process development in Information Technology to ensure effective utilization of business systems to support financial systems, supply chain operations, Learning Management (LMS), Human Resources Information Systems (HRIS), Customer Relationship Management (CRM) and our Enterprise Content Management (ECM) system.

    The individual will report to the head of Information Technology and own the technical implementation of the Enterprise Resource Program (ERP) system (Oracle E-Business Suite, R12) and will manage ERP users, create/review training content, assist to improve business processes related to ERP usage and manage Enterprise IT functions.

    This individual will work closely with functional leadership within Insmed to assure effective utilization, including modules to support manufacturing, finance, preventative maintenance, inventory management, HRIS, ECM and to support site strategies, including a Business Intelligence platform for performance monitoring. The candidate may also lead one or more strategic projects that have cross-functional impacts and significant value to the success of the business objectives. This includes architecting infrastructure enhancements specific to worldwide growth."

    Sentiment: Strong Buy

INSM
21.96-0.39(-1.74%)May 28 4:00 PMEDT